Monday, July 16, 2012
The French and German
reimbursement systems use the same definition of pharmaceutical innovation:
additional medical benefit versus a comparator. But differences in each
approach mean the outcomes will not always be the same.
According to reimbursement
consultants contacted by BioCentury, Germany's AMNOG system is more
quantitative and uses a narrower definition that is less accepting of surrogate
markers for patient benefit, while the French system is more pragmatic in its
determinations of additional benefit.